Carmel Wroth
Carmel Wroth is a senior health editor for NPR's Science Desk, where she guides digital strategy for the health team and conceives and edits digital-first, enterprise stories and packages.
Formerly, she founded and managed Side Effects Public Media, a public radio collaborative covering public health in the Midwest. Wroth also served as an editor at Yoga Journal for five years.
-
The Make America Healthy Again commission is proposing more than 100 moves to address the root causes of childhood chronic disease. Critics say other Trump administration moves contradict the goals. -
The health secretary announced a push to eliminate petroleum-based colorants from the food supply. But he'll need to get food companies on board. -
Researchers and advocates have pushed back at what they consider inaccurate and stigmatizing comments made by the health secretary, and note the causes of autism are complex. -
Health agency staffers describe a week of widespread uncertainty about who still has a job and how the work will get done as thousands of "reduction in force" notices went out beginning April 1. To many it's the opposite of "government efficiency." -
Federal health agencies have to slash their spending on contracts by more than a third, on top of the 10,000-person staffing cuts which started this week. -
Staffers began receiving termination notices this morning as part of a major restructuring at HHS. Some senior leadership are on their way out too. -
A survivor of childhood polio, Sen. Mitch McConnell was the only Republican in the Senate to vote no. Here's how he explained his vote. -
Two letters from different groups of senators call for answers from the Trump administration about pauses in scientific communications and funding. -
In announcing his pick, Trump said Oz will work closely with RFK Jr. "to take on the illness industrial complex." Oz, a celebrity physician, ran unsuccessfully for the U.S. Senate in 2022. -
The influential US Preventive Services Task Force urged behavioral counseling for children and teens with very high BMI. Notably the group did not include Ozempic-like drugs in the recommendation.
